当前位置:首页 - 行情中心 - 多瑞医药(301075) - 财务分析 - 现金流量表

多瑞医药

(301075)

  

流通市值:69.84亿  总市值:69.84亿
流通股本:8000.00万   总股本:8000.00万

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金43,172,346.3186,567,606.94171,654,185.42113,406,967.88
  收到其他与经营活动有关的现金433,912.7810,915,666.37260,085.653,821,127.3
  经营活动现金流入小计43,606,259.08197,483,273.31171,914,271.07117,228,095.18
  购买商品、接受劳务支付的现金48,492,059.79104,915,236.1107,668,991.2572,754,460.42
  支付给职工以及为职工支付的现金19,780,310.473,107,715.4148,502,565.0434,657,131.47
  支付的各项税费693,111.338,823,054.458,162,520.685,937,263.8
  支付其他与经营活动有关的现金11,293,284.9656,469,695.9442,306,223.5730,514,646.18
  经营活动现金流出小计80,258,766.48243,315,701.9206,640,300.54143,863,501.87
  经营活动产生的现金流量净额-36,652,507.4-45,832,428.59-34,726,029.47-26,635,406.69
二、投资活动产生的现金流量:
  收回投资收到的现金25,000,000921,983,0001,035,592,216.8770,592,216.8
  取得投资收益收到的现金144,480.473,277,925.676,285,947.275,086,794.54
  处置固定资产、无形资产和其他长期资产收回的现金净额408,817.6775,996.59--
  处置子公司及其他营业单位收到的现金净额-8,800,000--
  收到的其他与投资活动有关的现金-252,899,763.1924,434,549.8424,434,549.84
  投资活动现金流入小计25,553,298.071,187,736,685.451,066,312,713.91800,113,561.18
  购建固定资产、无形资产和其他长期资产支付的现金42,696,360.19101,816,834.9958,381,896.7540,422,725.97
  投资支付的现金5,000,000812,987,000981,000,000659,000,000
  取得子公司及其他营业单位支付的现金--15,152,526.8415,152,526.84
  支付其他与投资活动有关的现金-100,348,060.525,101,821.01103,107,145.62
  投资活动现金流出小计47,696,360.191,015,151,895.491,079,636,244.6817,682,398.43
  投资活动产生的现金流量净额-22,143,062.12172,584,789.96-13,323,530.69-17,568,837.25
三、筹资活动产生的现金流量:
  吸收投资收到的现金--2,190,5002,190,500
  取得借款收到的现金-127,700,000117,700,00080,000,000
  收到其他与筹资活动有关的现金56,442,970.07180,0008,082,3265,000,000
  筹资活动现金流入小计56,442,970.07127,880,000127,972,82687,190,500
  偿还债务支付的现金16,000,000183,909,09681,400,00072,400,000
  分配股利、利润或偿付利息支付的现金1,481,267.238,789,100.157,051,001.954,904,902.6
  支付其他与筹资活动有关的现金-86,774,994.34165,000165,000
  筹资活动现金流出小计17,481,267.23279,473,190.4988,616,001.9577,469,902.6
  筹资活动产生的现金流量净额38,961,702.84-151,593,190.4939,356,824.059,720,597.4
四、汇率变动对现金及现金等价物的影响--1,462.29--
五、现金及现金等价物净增加额-19,833,866.68-24,842,291.41-8,692,736.11-34,483,646.54
  加:期初现金及现金等价物余额85,278,030.5110,118,321.91262,128,315.39262,128,315.39
  期末现金及现金等价物余额65,444,163.8285,276,030.5253,435,579.28227,644,668.85
补充资料:
  净利润--132,401,390.23--59,856,560.2
  资产减值准备-5,992,360.28-3,118,234.9
  固定资产和投资性房地产折旧-46,959,981.83-21,447,769.29
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-46,959,981.83-21,447,769.29
  无形资产摊销-2,194,957.39-926,415.18
  长期待摊费用摊销-318,955.98-117,360.69
  处置固定资产、无形资产和其他长期资产的损失-105,451.29-9,561.89
  固定资产报废损失-827,649.25--
  公允价值变动损失--38,583.78--
  财务费用-17,937,693.71-38,219.17
  投资损失--852,610.79--1,019,573.96
  递延所得税--647,307.09-1,195,388.99
  其中:递延所得税资产减少--400,169.55-1,315,568.24
    递延所得税负债增加--247,137.54--120,179.25
  存货的减少--43,511,247.61--3,374,986.07
  经营性应收项目的减少-16,288,110.96--3,165,321.66
  经营性应付项目的增加-25,996,601.96-12,775,852.43
  其他-11,837,463.65--
  现金的期末余额-85,276,030.5-227,644,668.85
  减:现金的期初余额-110,118,321.91-110,118,321.91
  减:现金等价物的期初余额---152,009,993.48
  现金及现金等价物的净增加额--24,842,291.41--34,483,646.54
公告日期2026-04-292026-04-292025-10-242025-08-27
审计意见(境内)标准无保留意见
TOP↑